Office of Technology Transfer
About Harvard UniversitySee more information at Harvard Biological Laboratories.
515 articles with Harvard University
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
Orig3n, a Boston-based biotech company, today announced a research collaboration agreement with Harvard University, led by a faculty member from the Harvard Stem Cell Institute (HSCI), to develop cell therapies for the treatment of cardiovascular disease.
Watertown, Massachusetts-based Lyra Therapeutics closed a Series B financing worth $29.5 million. Its lead compound is LYR-210, which the company plans to take into a Phase II clinical trial for chronic rhinosinusitis
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
APEIRON EXPANDS EXECUTIVE BOARD AND APPOINTS DR. ANDERSON GAWECO AS CHIEF MEDICAL AND SCIENTIFIC OFFICER (CMSO)
APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).
The startup company will initially focus on infants suffering from neonatal abstinence syndrome.
Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard
Elysium Health, Inc.™ has entered into an exclusive license agreement with Mayo Clinic and Harvard University.
The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process.
Under the agreement, Symbiotix gains access to a portfolio of intellectual property developed in the laboratory of Dennis Kasper, M.D., William Ellery Channing Professor of Medicine and Professor of Microbiology and Immunobiology at Harvard Medical School.
Three-way Collaboration with the U.S. Army, Harvard University and Frequency Therapeutics to Focus on Progenitor Cell Regeneration in Muscle
The program is focused on small-molecule therapeutics to address several disease indications and conditions involving muscle.
The license, coupled with the existing license through the Broad Institute of MIT and Harvard, allows Charles River to offer custom in vivo and in vitro genome editing.
Mustang Bio Announces License Agreement With Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
Under the deal, technologies related to the development of off-the-shelf CAR T, as well as CRISPR/Cas9 gene editing platforms, will be utilized in conjunction with Mustang’s CAR T cell therapies.
Bayer and the Broad Institute of MIT and Harvard Expand Partnership to Advance Drug Discovery Research for Novel Cancer Treatments
Bayer and the Broad Institute of MIT and Harvard announced today that they have extended their multi-disciplinary research partnership by an additional five years, to develop and advance novel cancer treatments.
Syngenta Obtains Non-Exclusive IP License From Broad Institute for CRISPR-Cas9 Genome-Editing Technology for Agriculture Applications
CRISPR-Cas9 genome editing technology complements Syngenta’s already robust plant breeding innovation toolbox
Harvard’s Rudolph Tanzi, Ph.D., A Leader In Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board